Key Role of Phosphoinositide 3-Kinase Class IB in Pancreatic Cancer

Charlotte E. Edling1, Federico Selvaggi1,2, Richard Buus1, Tania Maffucci1, Pierluigi Di Sebastian3, Helmut Friess3, Paolo Innocenti3, Hemant M. Kocher2, and Marco Falasca1

Abstract

Purpose: Phosphoinositide 3-kinase (PI3K) signaling is well established as important in cancer. To date most studies have been focused on the PI3K/p110α isoform, which has been found to be mutated in several different cancers. The aim of our study was to determine which specific PI3K isoforms are involved in pancreatic ductal adenocarcinoma (PDAC) and investigate the effects of these isoforms on proliferation, survival, and induction of Akt activation in pancreatic cancer cells.

Experimental Design: The expression of all PI3K isoforms and downstream targets was analyzed by immunohistochemistry in human pancreatic cancer tissue and normal counterparts. Isoform selective inhibitors and short interfering RNA (siRNA) were employed to investigate the effects of the different PI3Ks on proliferation, survival, and intracellular signaling in PDAC cell lines.

Results: Immunohistochemical screening revealed high specific expression of the PI3K/p110γ isoform. Scoring indicated that 72% of the PDAC tissue stained positive for PI3K/p110γ, whereas no stain was detected in normal pancreatic ducts. Proliferation analyses after selective inhibition and siRNA downregulation of PI3K/p110γ showed that PI3K/p110γ, but not other PI3K isoforms, was required for cell proliferation. Overexpression of PI3K/p110γ indeed increased cell numbers and mediated activation of Akt in PDAC cell lines. Moreover, PI3K/p110γ was required for Akt activation via lyso-phosphatidic acid receptors.

Conclusions: These data represent the first identification of a tumor-specific accumulation of the PI3K isoform p110γ in human cancer. Further, our results signify a critical role for PI3K/p110γ in pancreatic cancer, and we hypothesize that PI3K/p110γ overexpression is a key event in the disease progression.

Pancreatic cancer has one of the poorest prognoses among all cancers because of its tendency for late discovery and its peculiar resistance to chemotherapy and radiation therapy (1, 2). The 5-year survival rate for pancreatic cancer is the lowest among all cancers (3). Although pancreatic cancer is well characterized at genetic level, the molecular mechanisms linking the genetic changes to the aggressive nature of this disease remain poorly understood. Studies using pancreatic tumor tissues and pancreatic cancer cell lines have identified a number of common genetic and epigenetic events. Mutations in K-Ras oncogene accumulate early in the disease progression and occur in 75% to 90% of pancreatic adenocarcinomas (4, 5). A key downstream target of the Ras family is phosphoinositide 3-kinase (PI3K), the enzyme responsible for generation of 3-phosphorylated phosphoinositides and activation of the protein kinase B/Akt (6–9). Activation of Akt represents a biological indicator of the aggressiveness of pancreatic cancer (10–12), and preclinical studies have shown that generic inhibitors of PI3K, such as wortmannin and LY294002, induce apoptosis and inhibit tumor growth of pancreatic cancer xenografts (13). In addition to activated Akt in general, the Akt2 isoform has been shown to be overexpressed to some extent (10, 14). It is yet not known what specifically activates Akt in pancreatic cancer, but there are no reports suggesting that Akt itself is mutated (15–17).

The PI3K/Akt pathway is involved in inhibition of apoptosis and stimulation of cell proliferation (9, 18). It is now well known that deregulation of intracellular signaling...
mediated by the family of PI3K enzymes is associated with cancer development, such that up to 50% of all cancer types exhibit deregulation of this signaling pathway (19). Three classes of PI3Ks have been described (20, 21), with PI3K class I divided into two groups: class IA and class IB. Class IA encompasses three isoforms of the catalytic subunit known as p110α, p110β, and p110δ, whereas class IB has the single p110γ. Gain of p110α function by mutation is common in several human cancers (22, 23). The potential contribution to cancer initiation and progression by the other isoforms has not been fully investigated. Although no somatic mutations of the genes encoding p110β, p110γ, and p110δ have been reported so far, an increased expression of the p110β and p110δ isoforms has been observed in some colon and bladder tumors, and in glioblastoma (24, 25). The p110β isoforms has been shown to stimulate cell proliferation and invasive cell growth (26); p110δ controls proliferation in acute myeloid leukemia (27) and migration of breast cancer cells (28), whereas a role has been suggested for p110γ in tumor angiogenesis (29) and drug resistance of chronic myeloid leukemia cells (30). Interestingly, it has been reported that overexpression of wild-type p110α does not seem to have transforming potential, whereas overexpression of the wild-type catalytic subunits p110β, p110γ, or p110δ is sufficient to induce an oncogenic phenotype in cultured cells (31). It has further been suggested that the transforming activity of the p110γ isoform depends on Ras binding (31). These data suggest that although the oncogenic potential of p110α is associated with mutations of the gene, elevated levels of wild-type p110β, p110γ, or p110δ might induce cellular transformation on their own.

**Translational Relevance**

In this study we screened pancreatic ductal adenocarcinomas and normal counterparts for constitutive expression of the different phosphoinositide 3-kinase (PI3K) isoforms, and we here reveal selective tumoral overexpression of the PI3K class IB catalytic subunit p110γ. Further, we show that PI3K/p110γ is necessary for pancreatic cancer cell line proliferation, indicating that overexpression of this specific PI3K isoform has a functional role in pancreatic cancer progression. These results suggest PI3K/p110γ as a rational target for development of novel therapeutic agents.

**Immunohistochemistry**

Informed consent was obtained as appropriate. Paraffin-embedded tissues were used for identification of indicated proteins in human cancer and donor samples. Briefly, deparaffinized and rehydrated sections were incubated in blocking solution (TBS, 3% bovine serum albumin) and sequentially incubated with primary antibodies [p110α, p110β, p110γ, and p110δ (Santa Cruz Biotechnology); anti-pSer473-Akt and phosphatase and tensin homolog deleted on chromosome ten (PTEN; Cell Signaling Technology); anti-PI3K-C2α and anti-PI3K-C2β (BD Transduction Laboratories); and anti–phosphatidylinositol 3,4,5-trisphosphate (PIP3), kindly provided by Prof Glenn Prestwich (University of Utah)], secondary biotinylated goat anti-rabbit, anti-mouse antibodies, and peroxidase-labeled streptavidin. Positive reactions were visualized by diaminobenzidine/hydrogen peroxide (DAKO) as substrate. The sections were counterstained with hematoxylin (Sigma). Control samples exposed to secondary antibodies alone did not show nonspecific staining.

**Cell lines**

Cell lines were cultured in RPMI 1640 supplemented with 10% fetal bovine serum, penicillin-streptomycin-L-glutamine, and gentamicin, all from Invitrogen. The cell lines ASPC1, PANC1, BXPC3, Capan1, HPAF, and PT45 had been short tandem repeat (STR) genotyped and confirmed identical to the published DNA profiles of the American Type Culture Collection. The PT45 was identical to an original vial from Dr. Kalthoff who established the cell line. The cell lines Dec-hTert and HPDE had been characterized previously and their authenticity was confirmed by Dr. Kocher. The cell lines GER, PaCa44, PSN1, MCC1, and CFPac were kindly provided by Prof. Aldo Scarpa (University of Verona, Italy) and had been characterized by his lab (32).

**Transfection of short interfering RNA and plasmid DNA**

Cells were transfected with human p110γ plasmid, kindly provided by Prof. B. Vanhaesebroeck (Queen Mary University London, United Kingdom), and pcDNA3 empty vector using Lipofectamine 2000 and Smartpool siRNA targeting p110α, p110β, p110δ, or p110γ (Thermo Fisher Scientific).
Fischer Scientific) using Oligofectamine according to Invitrogen’s respective protocols (Invitrogen). Transfection efficiency of siRNA was verified with real-time PCR analysis and Western blotting (Supplementary Fig. S3A-C and Fig. 6).

**Cell counting and MTT assay**

Cells were treated as indicated in the figures with inhibitors AS252424, TGX-221, IC87114 (kind gift from Prof. P.R. Shepherd, University of Auckland, New Zealand), and LY294002 (Calbiochem, Merck) or cells transfected with the indicated siRNA/DNA. The inhibitor concentrations used were chosen so as to be specific according to published IC50 values (34). Cells were counted on a CASY cell counter at indicated time points. MTT (Thiazolyl Blue Tetrazolium Bromide, M2128, Sigma) was diluted in experiment-specific culture media (0.5 mg/mL), incubated 2 hours, and dissolved in DMSO before the absorbance was read at 570 nm.

**Propidium iodide incorporation and Annexin V staining**

For the flow cytometry analysis cells were pretreated as described in the figures. Subsequently, cells were incubated for 30 minutes in propidium iodide (PI) solution [20 mmol/L Tris-HCL (pH 7.5), 100 mmol/L NaCl, 50 mg/mL PI, 0.1% Nonidet P40, and 20 μg/mL RNase] or stained with Annexin V and PI according to kit protocol (BD biosciences) before analysis on a Becton Dickinson LSR II analyzer.

**Caspase3 assay**

Cells were treated as described and the caspase-3 activity was assayed according to manufacturer’s protocol using the EnzChek Caspase-3 Assay Kit 2 (Invitrogen).

**Western blotting**

Cell pellets were prepared from the indicated cell lines cultured in normal growth media and lysed in buffer [150 mmol/L NaCl, 0.5% Triton X-100, 10 mmol/L Tris (pH 7.6), 5 mmol/L EDTA (pH 8.0), 30 mmol/L sodium pyrophosphate, 1 mmol/L sodium orthovanadate, 50 mmol/L sodium fluoride, 10% glycerol, 10 μg/mL aprotinin, 10 μg/mL leupeptin, and 100 mmol/L phenylmethylsulfonylfluoride] or in β-mercaptoethanol sample buffer. Complete lysates were separated on SDS-PAGE. For stimulation experiments cells were transfected with siRNA 72 hours prior to overnight starvation and then stimulated for 15 minutes. Alternatively, cells were starved overnight prior to a 30-minute pretreatment with inhibitors and a 15-minute stimulation with 25 μmol/L lysophosphatidic acid (LPA; Sigma) or 20 ng/mL epidermal growth factor (EGF; PeproTech). The gels were transferred to nitrocellulose membranes (Whatman) and blocked in 5% milk–PBS-Tween and incubated with antibodies: tubulin (Sigma), p110α, p110β, p110γ, PTEN, pThr308-Akt, pSer473-Akt (Cell Signaling Technology), and Akt (Santa Cruz Biotechnology) according to the manufacturers’ protocol. Membranes were incubated with horseradish peroxidase–conjugated secondary antibodies (Sigma), washed with PBS-Tween, and developed using ECLplus (GE healthcare).

**Statistics**

Error bars indicate SE. The P values were calculated with χ² test, Mann-Whitney U-test, or Students t-test as indicated in the figure legends. The χ² tests were calculated with one degree of freedom. Student’s t-test was calculated with the assumption of two-sample equal variance and two-tailed distribution or otherwise indicated. P values < 0.05 were considered significant.

**Results**

**PI3K Class IB isoform p110γ is overexpressed in human pancreatic cancer tissues and cell lines**

To investigate the molecular events associated with PI3K in pancreatic cancer we decided to do an immunohistochemical screening of the molecules involved in PI3K signaling in human pancreatic normal (healthy donors and nonneoplastic controls from areas surrounding tumors) and pancreatic ductal adenocarcinoma (PDAC) tissue. In the screening we analyzed the expression and distribution of the different isoforms of PI3K, as well as the lipid product PIP₃. Activation of the downstream target Akt was determined by monitoring phosphorylation at residue Ser473. In addition, expression levels of PTEN, which specifically dephosphorylates PIP₃, were determined.

Analysis of the PI3K class IA isoform p110α showed it to be expressed in both pancreatic normal and cancer tissue samples with similar nuclear distribution in both groups (Fig. 1). In normal samples the protein was present in ducts and in acini with different intensity grade. In PDAC tissues, p110α exhibited a strong staining in atrophic and distorted ducts and in atrophic acini. Staining for the PI3K class IA isoforms p110α and p110β was found to be weak or absent in most normal and cancer samples. Where detectable, p110β expression was found in acinar cells, smaller pancreatic ducts, intrapancreatic nerve fibers, and around blood vessels in the normal tissue. In the PDAC tissue p110β was strongly expressed in few of the neoplastic ducts and in inflammatory cells. The protein was localized in the cytoplasm in both groups. The p110δ isoform showed similar weak staining in normal and cancerous parts of the pancreas. Low expression levels were detected in ductal cells whereas stronger expression levels were observed in the islets of Langerhans. The images in Fig. 1 represent samples where positive stain was seen.

Interestingly, our analysis showed that the PI3K class IB isoform p110γ was not detectable at all in normal duct epithelium and acinar cells, whereas it showed a cytoplasmic localization in islet cells and nerve fibers. In contrast, high levels of the protein were observed in pancreatic cancer tissue. In particular p110γ was highly expressed in pancreatic intraepithelial neoplasia and ductal carcinoma, and
Fig. 1. Immunohistochemical analyses reveal overexpression of PI3K/p110γ in human pancreatic cancer. Immunohistochemical screening of PI3K classes I to III, PIP3, phosphorylated Akt, and PTEN in PDAC samples and normal controls. The expression of p110γ, phosphorylated Akt (Ser473), and PIP3 are visibly overexpressed in the PDAC samples. The pictures are of positively stained samples, one for normal and two distinct images for cancer. All stains of normal tissue depict pancreatic ducts. PDAC samples show atrophic acinar cells and dysplastic/aberrant ducts typical for pancreatic cancer. Examples of stained islets are displayed. Key features identified by morphology are indicated (on first occasions only): A, acinar cells; D, duct; V, blood vessel; I, islet; Inf, inflammatory cells/stroma. Magnification for all pictures, ×20.

<table>
<thead>
<tr>
<th></th>
<th>Normal</th>
<th>PDAC</th>
</tr>
</thead>
<tbody>
<tr>
<td>p110α</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p110β</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p110γ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p110δ</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI3K-C2α</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PI3K-C2β</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hVps34</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PIP3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p473-Akt</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTEN</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
it seemed to be localized both in the nuclear compartment and in the cytoplasm of these cells (Fig. 1). The PI3K class II isoform PI3K-C2α was expressed in a subset of the samples. Positive stain was found in acini and ducts in cancer and donor tissue, but with higher intensity staining in acini with high cellular atypia and in dysplastic ducts (cytoplasmic). The PI3K-C2β isoform was only visibly stained in few of the samples. In the positive samples the protein was expressed in ductal and acinar structures in both normal and cancer (cytoplasmic).

The PI3K class III enzyme human vacuolar protein sorting 34 (hVps34) was exclusively and strongly localized in subsets of Langerhans islets in both normal and cancer tissues (Fig. 1). Furthermore, the screening indicated that pancreatic cancer is also characterized by high levels of phosphorylated Ser473-Akt and PIP3. Phosphorylated Akt was visible with different intensity in the cytoplasm of neoplastic ductal cells and in atrophic acini, whereas it was only detectable in islets in the normal tissues, corroborating previous reports (10–12). PIP3 showed faint staining in acinar cells and ducts of the normal pancreas, but in the PDAC samples PIP3 was abundant in aberrant ducts and in atrophic acinar cells. Staining of PIP3 was detected in the cytoplasmic compartment. Finally, the phosphatase PTEN was expressed at similar levels mainly in acinar cells in both normal and PDAC tissue (Fig. 1).

To quantitate the immunohistochemical analysis of p110γ, the degree of staining (none, weak, moderate, or strong) and the number of positive ducts (0-100%) were scored manually in 12 control samples and 29 cancer samples, establishing a significance of all inhibitors used have been previously reported (34).

As shown in Fig. 4, chemical inhibition of p110γ with AS252424 specifically blocked proliferation in the pancreatic cancer cell lines HPDE and Capan1, as assessed by cell counting (Fig. 4A). The p110γ effect on proliferation was confirmed in ASPC1, HPAF, and PT45 by MTT assay (Supplementary Fig. S2A). No decrease of proliferation was observed upon specific inhibition of the p110β (TGX-221) and p110δ (IC87114) isoforms (Fig. 4A). On the contrary, selective inhibition of p110gamma slightly increased proliferation of Capan1 cells. As a control we used the PI3K generic inhibitor LY294002, which showed that complete inhibition of PI3K class I isoforms severely blocked proliferation, suggesting the existence of an alternative target. Downregulation of the PI3K class I isoforms using specific siRNAs in PT45 cells show that only the p110γ isoform had a significant effect on proliferation analyzed by cell counting, consistent with data obtained using isoform-selective inhibitors (Fig. 4B). The effect of p110γ downregulation was confirmed in HPAF cells assessed by cell counting and MTT (Fig. 4B and Supplementary Fig. S2B). Furthermore, we found that overexpression of exogenous p110γ in ASPC1 cells increased the proliferative activity assessed by MTT (Fig. 4C). Specificity and efficiency for siRNA downregulation was validated at mRNA as well as protein level (Supplementary Fig. S3A and B and Fig. 6A). The overexpression of p110γ was further validated at mRNA level (Supplementary Fig. S3C).

Examination of the cell cycle state upon p110γ inhibition displayed accumulation of cells in G2-M phase (Fig. 4D). General inhibition of PI3K isoforms with LY294002 resulted in G1 arrest, whereas no effect on the cell cycle was observed in cells treated with the p110δ- and p110δ-specific inhibitors alone (Fig. 4D).

To investigate if inhibition of p110γ activity induced apoptosis we analyzed caspase-3 activity (Fig. 5A) and Annexin V binding (Fig. 5B) following treatment with the p110γ-specific inhibitor AS252424. Caspase-3 activity, which is a relatively early indicator of apoptosis, was measured after 24 hours. The results indicated that p110γ inhibition did not induce apoptosis at the concentration...
(1 μmol/L) sufficient to block proliferation. However, treatment with 10 times higher concentration (10 μmol/L) did induce apoptosis, possibly because of off-target effects of the inhibitor. The general PI3K inhibitor LY294002 was able to induce apoptosis in the Capan1 cell line (Fig. 5A). Annexin V staining was used to measure apoptosis at a later time point. The cells were treated for 3 days with AS252424 or with LY294002. Consistent with the caspase-3 activity assay, p110γ inhibition did not induce apoptosis when used at the lower concentration. At higher concentration (10 μmol/L) almost all cells died after 3 days of incubation. Generic inhibition of PI3Ks increased the number of apoptotic cells although not reaching statistical significance (Fig. 5B).

**p110γ blockade inhibits LPA-induced Akt activation in pancreatic cancer cells**

To further analyze the PI3K pathway we determined the effect of blockade of the different PI3K isoforms on Akt activation in HPAF and PT45 cell lines. The phosphorylation status (p-S473 and p-T308) of Akt was assessed by Western blotting after downregulation with siRNA or pretreatment with the isoform-selective inhibitors and stimulation with either LPA or EGF (Fig. 6). The PI3K class IB isoform is believed to be mainly activated via G-protein coupled receptors and not via tyrosine kinase receptors (21). Consistently, experiments using selective siRNAs revealed that p110γ was indeed required for full activation of Akt upon LPA, but not EGF, stimulation. Further, we found that...
p110β was required for activation of Akt following both LPA and EGF stimulation, consistent with data suggesting that p110β can be activated both via tyrosine kinase receptors and G-protein coupled receptors (21). Noticeably, neither p110α nor p110δ seemed to play a role in the Akt activation in this cell system (Fig. 6A). Moreover, pretreatment with inhibitors show that p110γ is required for Akt activation in the PT45 and HPAF cell lines. Surprisingly, p110β inhibition had effect in the PT45 cell line but not in the HPAF cell line. The general PI3K inhibitor LY294002 blocked Akt phosphorylation in both cell lines as expected (Fig. 6B). Additionally,
Western blot analysis of ASPC1 and Dec-hTert cells transiently transfected with wild-type p110γ shows increased phosphorylation of Akt in correlation with overexpressed p110γ (Fig. 6C). These results, in combination with the immunohistochemistry screening, indicate that Akt activation detected in pancreatic cancer might be specifically driven by overexpression of the PI3K isoform p110γ.

**Discussion**

Several studies have established that many growth factors and their receptors are overexpressed in human pancreatic cancer (1). These alterations in signal transduction pathways confer an enormous survival and growth advantage to pancreatic cancer cells. Thus, there is intense interest in the molecular mechanisms of pancreatic cancer to understand its particular aggressiveness and resistance to drug treatments. Several lines of evidence indicate a crucial
role of the PI3K enzymes in human cancer biology, and deregulation of the PI3K-Akt pathway is also implicated in pancreatic cancer (10, 18). So far, however, the majority of studies have been focused on the PI3K isoform p110α. Therefore, the question was whether the "non α" PI3K isoforms could also play a role in cancer biology.

This study represents the first detailed analysis of PI3K pathway expression in human pancreatic cancer. We identified the p110γ isoform as being selectively overexpressed in pancreatic cancer, and we show that p110γ is necessary for pancreatic cancer cell proliferation. Cell cycle analysis indicates that p110γ participates in driving the cell through the G2–M phase. Hence, lack of p110γ slows down proliferation, whereas inhibition of other PI3Ks seems to result in G1 arrest in combination with induction of apoptosis, leading to decreased proliferation and eventually cell death. More detailed investigations of all the known players in the cell cycle machinery are required before conclusions regarding the mechanism behind this can be drawn. Interestingly, we find that the low concentration of inhibitor, sufficient to block proliferation, does not induce apoptosis, although ten times higher concentration does. We believe this is most likely due to off-target effects of the inhibitor. This is further supported by our data indicating that the LY294002 compound is able to induce apoptosis and to completely inhibit Akt activation in pancreatic cancer cell lines in which p110γ inhibition has only a partial effect. This is an intriguing hypothesis, and therefore the identification of this additional target, i.e., another kinase in the PI3K pathway, may provide us the opportunity to completely block pancreatic cell growth by hittiing two different targets. Furthermore, in this study we show that p110γ and p110β, but not p110α and p110δ, are required for activation of Akt. Because the p110β isoform is not expressed in most of the examined tissue samples, this indicates that the overexpression of the p110γ isoform is responsible for the detected activation of Akt in the cancer tissue. This is supported by our data showing that overexpression of p110γ itself indeed can increase the level of phosphorylated Akt in the ASPC1 and Dec-hTert cell lines.

Chronic inflammatory disorders are often associated with an increased risk of developing cancer. A classic example of the connection between inflammation and cancer is the increased risk of pancreatic cancer in patients with chronic pancreatitis (35). Furthermore, chronic pancreatitis accelerates cancer progression in genetically engineered mouse models and is essential for induction of PDAC by K-Ras oncogenes in adult mice (36). Genetic targeting of p110γ and p110δ in mice has underlined a central role of these PI3K isoforms in inflammation (37). Therefore, it is important to emphasize that p110γ expression was also observed in patients with inflammation of the pancreas (Supplementary Fig. S4). These data are in agreement with a recent finding suggesting a role for p110γ in the development of pancreatitis (38). We hypothesize that p110γ expression and activation could be an early event that links chronic pancreatitis and pancreatic adenocarcinoma, but further studies are needed to show this link. The potential role of p110γ in inflammatory cells and in pancreatic cancer cells gives us the appealing opportunity to target both tumor cell as well as inflammation.

In summary our findings represent the first identification of a cancer-specific expression of class IB PI3K and the first clear showing of a link among p110γ expression, Akt activation, and pancreatic cancer progression. Furthermore, our data firmly support the emerging hypothesis that deregulation of PI3Ks in cancer may not be only restricted to mutations of the p110α but also include overexpression of other PI3K isoforms. These data strongly signify the PI3K isoform p110γ as a potential therapeutic target in the prevention and treatment of pancreatic cancer.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

C.E. Edling was supported by the European Commission FP6 program ApoTherapy (GRD7344, grant to M. Falasca) and by the Pancreatic Cancer Research Fund (PCRF, grant to M. Falasca and C.E. Edling). R. Ruus was supported by PCRF (grant to M. Falasca). We thank Prof. Lewis Cantley (Harvard Medical School) and Prof. Bart Vanhaesebroeck (Queen Mary University London, United Kingdom) for critically reading the manuscript, Prof. Mauro Piantelli (University of Chieti, Italy) for support with immunohistochemical analysis, Prof. Peter Shepherd (University of Auckland, New Zealand) for the PI3K inhibitors, Prof. Aldo Scarpa (University of Verona, Italy) for the pancreatic cancer cell lines, and Dr. Paul Nielsen (Echelon, USA) and Prof Glenn Prestwich (University of Utah) for the anti-phosphoinositide antibodies.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 05/07/2010; revised 08/16/2010; accepted 08/20/2010; published OnlineFirst 09/28/2010.

References

7. Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J. Matrix adhesion and Ras transformation both activate...


# Clinical Cancer Research

## Key Role of Phosphoinositide 3-Kinase Class IB in Pancreatic Cancer


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-10-1210</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Cited articles</th>
<th>This article cites 36 articles, 14 of which you can access for free at: <a href="http://clincancerres.aacrjournals.org/content/16/20/4928.full#ref-list-1">http://clincancerres.aacrjournals.org/content/16/20/4928.full#ref-list-1</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Citing articles</td>
<td>This article has been cited by 11 HighWire-hosted articles. Access the articles at: <a href="http://clincancerres.aacrjournals.org/content/16/20/4928.full#related-urls">http://clincancerres.aacrjournals.org/content/16/20/4928.full#related-urls</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>